

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number  
**WO 2004/022037 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 9/16**, 47/32

(21) International Application Number:  
PCT/IB2003/003779

(22) International Filing Date:  
4 September 2003 (04.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
903/DEL/2002 4 September 2002 (04.09.2002) IN

(71) Applicant (for all designated States except US): **RAN-  
BAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru  
Place, 110019 New Delhi, Delhi (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MURPANI,  
Deepak** [IN/IN]; C-213, Lajpat Nagar - I, 110024 New  
Delhi, Delhi (IN). **ARORA, Vinod, Kumar** [IN/IN]; 20B,  
DG-II, Vikas Puri, 110018 New Delhi, Delhi (IN). **MA-  
LIK, Rajiv** [IN/AT]; Haus 13/4, Unterer Schreiberweg,  
A-1190 Wien (AT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



**WO 2004/022037 A1**

(54) Title: TASTE MASKED DOSAGE FORMS AND PROCESSES FOR THEIR PREPARATION

(57) Abstract: The invention relates to taste masked dosage forms utilizing low amounts of taste masking polymer, and simple and economical processes for the preparation of the taste masked dosage forms. The taste-masked dosage form includes one or more drugs and one or more cationic polymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters. The wt/wt ratio of the drug to polymer is less than about one to two.

## TASTE MASKED DOSAGE FORMS AND PROCESSES FOR THEIR PREPARATION

### Field of the Invention

The technical field of the invention relates to taste masked dosage forms utilizing  
5 low amounts of taste masking polymer, and simple and economical processes for the  
preparation of such taste masked dosage forms.

### Background of the Invention

Many patients, especially children and elderly, have trouble in swallowing whole  
tablets and even capsules. It is therefore desirable to administer drugs to such patients  
10 either as a liquid dosage form or as a fast dissolving or fast disintegrating solid dosage  
form. Fast dissolving or disintegrating solid dosage forms, due to their ease of  
administration and pleasant taste, may encourage patients to adhere to daily medication  
regimens and therefore provide better compliance. These dosage forms combine the  
advantages of both liquid and conventional tablet formulations, and also offer advantage  
15 over both traditional dosage forms. For example, they provide the convenience of a tablet  
formulation while also allowing the ease of swallowing provided by a liquid formulation.  
They also allow the luxury of much more accurate dosing than the primary alternative,  
oral liquids.

Palatability and "mouth feel" are among the most important characteristics to be  
20 considered in providing fast dissolving or disintegrating solid dosage forms, or matrix, for  
a drug. Unfortunately, many drugs have a bitter or otherwise unpalatable taste, or an  
unacceptable mouth feel, which make such drugs unsuitable for administration as fast  
dissolving or fast disintegrating dosage forms. Much research has been devoted to  
designing techniques and approaches to mask the bitter taste of drug in dosage forms.  
25 Simple approaches include adding chemicals mediating, flavoring or sweetening  
ingredients to the composition, which thereby mask the bitterness of the drug. When  
simple approaches are ineffective, drug modifying approaches are used in which the  
dosage form is so formulated that the drug's dissolution in the mouth is retarded or  
prevented by physical and/or chemical means. One such approach to retard by physical  
30 means is to embed or encapsulate the drug within a wall or barrier material that physically

separates it from the saliva. Cationic copolymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid have been employed as the barrier material in various taste-masked formulations. In some cases, these polymers are also known to modify taste by chemically interacting with drugs.

5 For instance, U.S. Patent No. 5,286,489 discloses a method of preparing taste masked dosage forms of active ingredients having an amine or amido groups by making a porous drug-polymer matrix with Eudragit® E-100. U.S. Patent No. 5,275,823 discloses a chewable tablet that includes a granulate of a histamine H<sub>2</sub>-receptor antagonist and Eudragit E® 100, and an admixture of a taste-masking extragranular water-insoluble  
10 hygroscopic excipient. U.S. Patent No. 5,489,436 discloses a chewable medicament tablet that includes a medicament coated with a taste-masking amount of a polymer blend of dimethylaminoethyl methacrylate and neutral methacrylic acid esters and a polymer selected from cellulose acetate and cellulose triacetate. U.S. Patent No. 4,708,867 discloses a mini pellet dosage form of prednisone. The dosage form includes a nonpareil  
15 seed coated with a first layer of the drug and a second layer of a copolymer of dimethylaminoethyl methacrylate and methyl methacrylate. U.S. Patent No. 4,760,093 discloses a taste neutral powder form of spray-dried acetaminophen which includes about 60% to 74% by weight acetaminophen and about 26% to 40% by weight of a copolymer that is cationic in character and is based on dimethylaminoethyl methacrylate and neutral  
20 methacrylic acid esters.

U.S. Patent No. 6,153,220 discloses use of cationic copolymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters in amounts significantly greater than the amount of drug in need of taste masking to form with the drug a taste masked micromatrix powder. The drug and the copolymer (e.g., Eudragit® E  
25 100) are in the form of micromatrices having an average size from about 1 µm to 125 µm. The '220 patent states that the ratio of copolymer to drug is greater than two to one and that the prior art does not teach the advantageous use of employing cationic copolymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters in amounts significantly greater than the amount of drug in need of taste masking to form  
30 with the drug a taste-masked micromatrix powder.

The processes used for taste masking in the patents listed above involve multiple steps which are technically complicated and difficult to reproduce, besides being

economically disadvantageous. Moreover the recommended limit by FDA for oral intake of polymer with a dimethylaminoethyl group is quite low and therefore these polymers in practice cannot be used in higher amounts. Therefore, there still exists a need for taste masked dosage forms utilizing low amounts of cationic polymers.

5

### Summary of the Invention

In one general aspect there is provided a taste-masked pharmaceutical dosage form that includes one or more drugs and one or more cationic polymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters. The wt/wt ratio of the drug to polymer is less than about one to two.

10


Embodiments of the dosage form may include one or more of the following features. For example, the wt/wt ratio of the drug to polymer may be less than approximately 1:1.7 or less than approximately 1:1.5.

The drug may be one or more of H<sub>2</sub> receptor antagonists, antibiotics, analgesics, cardiovascular agents, peptides or proteins, hormones, anti-migraine agents, anti-coagulant agents, anti-emetic agents, anti-hypertensive agents, narcotic antagonists, chelating agents, anti-anginal agents, chemotherapeutic agents, sedatives, anti-neoplastics, prostaglandins, drugs for erectile dysfunction, drugs acting on central nervous system, anti-diarrhoeal and anti-diuretic agents. The drug may be one or more of nizatidine, cimetidine, ranitidine, famotidine, roxatidine, etomidate, loperamide, nifedipine, niperitone, sulfotidine, tuvatidine, zaltidine, erythromycin, penicillin, ampicillin, roxithromycin, clarithromycin, psyllium, ciprofloxacin, theophylline, nifedipine, prednisone, prednisolone, ketoprofen, acetaminophen, ibuprofen, dexibuprofen lysinate, flurbiprofen, naproxen, codeine, morphine, sodium diclofenac, acetylsalicylic acid, caffeine, pseudoephedrine, phenylpropanolamine, diphenhydramine, chlorpheniramine, dextromethorphan, berberine, mefenamic acid, flufenamic acid, astemizole, terfenadine, phenytoin, guaifenesin, N-acetylprocainamide HCl and pharmaceutically acceptable salts or derivatives thereof.

The drug may be one more unpleasant tasting drugs. The drug may be a low dose drug and the low dose drug may be one or more of enalapril, lorazepam, zolmitriptan, domperidon, selegiline, ondansetron, mirtazepine, hyosyamine sulphate, risperidone, citalopram, olanzapine, rizatriptan, piroxicam, desloratadine, cetirizine,

loperamide, sildenafil, topiramate, and pharmaceutically acceptable salts or derivatives thereof.

The cationic polymer may include a dimethylaminoethyl group. The cationic polymer may have the following formula:



5

where:  $R^1 = R^3 = \text{CH}_3$

$R^2 = \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$

$R^4 = \text{CH}_3, \text{C}_4\text{H}_9.$

The cationic polymer may be a polymers commercially available as Eudragit®. The Eudragit® may be one or both of Eudragit® E-100 and Eudragit® EPO.

10

The taste masked pharmaceutical dosage form may further include other additives. The additives may be one or more of cellulose ester, talc, magnesium stearate and pigments. The cellulose ester may be one or more of cellulose acetate, cellulose acetate butyrate, cellulose triacetate, ethyl cellulose and mixtures thereof.

15

A drug solution/dispersion may be coated onto a water soluble or insoluble inert core. The water soluble or insoluble inert core may include one or more of directly compressible dibasic calcium phosphate, directly compressible sugar, microcrystalline cellulose, and nonpareil sugar seeds. The inert core may be directly compressible mannitol. The inert core may have a particle size greater than about 100


20

microns.

The dosage form may be one or more of sprinkles, chewable tablets, mouth dissolving tablets, water dispersible tablets, effervescent tablets and suspensions. The dosage form may further include one or more pharmaceutically inert excipients. The one or more pharmaceutically inert excipient may be one or more of diluents, binders, 5 disintegrants, coloring agents, flavoring agents, stabilizers, surfactants, lubricants, glidants, plasticizers and preservatives.

In another general aspect there is provided a process for the preparation of a taste masked dosage form of one or more unpleasant tasting drugs. The process includes dissolving or dispersing one or more drugs and one or more cationic polymers 10 in a solvent; and loading a solution and/or dispersion of one or more drugs and one or more cationic polymer onto an inert core. The wt/wt ratio of the drug to polymer in the dosage form is less than about one to two. The one or more cationic polymers are synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters

Embodiments of the process may include one or more of the features described 15 above or the following features. For example, the loading of the drug solution/dispersion over the inert core may be carried out by one or more of granulation, spray coating or coacervation technique. The solvent may include one or more of acetone, methanol, ethyl alcohol, isopropyl alcohol, water, n-butyl alcohol, propylene glycol, ethylene glycol, monobutyl ether, methyl ethyl ketone, 20 cyclohexanone, methylene chloride, chloroform, carbon tetrachloride, trichloroethylene, tetrachloroethylene, ethyl acetate, n-butyl acetate, propylene glycol acetate, toluene and mixtures thereof. The cationic polymer may include a dimethylaminoethyl group. The cationic polymer may have the following formula:



where:  $R^1 = R^3 = \text{CH}_3$


$R^2 = \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$

$R^4 = \text{CH}_3, \text{C}_4\text{H}_9$ .

- 5 The cationic polymer may include a polymer commercially available as Eudragit®. The Eudragit® may be one or both of Eudragit® E-100 and Eudragit® EPO.

- In another general aspect there is provided a taste masked pharmaceutical dosage form that includes an inert core; one or more drugs; and one or more cationic polymers. The one or more cationic polymers are synthesized from
- 10 dimethylaminoethyl methacrylate and neutral methacrylic acid esters, the one or more drugs and the one or more cationic polymers form a layer around the inert core, and the wt/wt ratio of the drug to polymer in the dosage form is less than about one to two.

- Embodiments of the dosage form may include one or more of the features described above or the following features. For example, the cationic polymer may
- 15 include a dimethylaminoethyl group. The cationic polymer may have the following formula:



where:  $R^1 = R^3 = \text{CH}_3$

$R^2 = \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$

$R^4 = \text{CH}_3, \text{C}_4\text{H}_9.$

- 5 The cationic polymer may be a polymer commercially available as Eudragit®. The Eudragit® may be one or both of Eudragit® E-100 and Eudragit® EPO.

The inert core may be one or more of directly compressible dibasic calcium phosphate, directly compressible sugar, microcrystalline cellulose, and nonpareil sugar seeds.

- 10 The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects, and advantages of the inventions will be apparent from the description and the claims.

### **Detailed Description of the Invention**

- The present invention involves a single step process for the preparation of a taste masked dosage form which requires low amounts of cationic polymer. Hence, there is provided a taste masked dosage form comprising unpleasant tasting drug and low amount of cationic polymer. The cationic polymer may have a dimethylaminoethyl group. In another general aspect there is provided a process for the preparation of the taste masked dosage form of unpleasant tasting drug wherein the process includes loading of a solution/dispersion of the drug and the low amount of cationic polymer on to an inert core. Again, the cationic polymer may have a dimethylaminoethyl group. In particular, the
- 15
- 20



weight ratio of the amounts of drug and cationic polymer in the dosage form is less than about one to two.

The taste masked dosage forms are prepared by dispersing and/or dissolving one or more drugs and one or more cationic polymers in a solvent and loading this solution or dispersion onto cores. Unlike other processes in which a separated drug coat and polymer coat is used in a multi-step process, the taste masked dosage forms are formed in a single step process. Moreover, the quantity of the polymer required to mask the unpleasant taste of the drug is reduced relative to the prior art multi-step processes, which is not only economical, but also provides better maneuverability for other excipients. Further, it provides a physical polymeric barrier, which completely embeds and/or surrounds the drug particles unlike in other coating processes in which the particle shape or deposition in a dead zone may not allow complete particle coating. Further, as the drug and polymer get mixed intimately, it prevents breaking of taste masking coating by mastication. Moreover complete solubility of the cationic polymer with a dimethylaminoethyl group in acidic pH assures complete drug dissolution in the upper gastro intestinal tract.

These drug-loaded cores may be further processed into dosage forms such as sprinkles, chewable tablets, mouth dissolving tablets, water dispersible tablets, effervescent tablets and suspensions.

Examples of the therapeutic categories of drugs suitable for the taste masked dosage form include H<sub>2</sub> receptor antagonists, antibiotics, analgesics, cardiovascular agents, peptides or proteins, hormones, anti-migraine agents, anti-coagulant agents, anti-emetic agents, anti-hypertensive agents, narcotic antagonists, chelating agents, anti-anginal agents, chemotherapy agents, sedatives, anti-neoplastics, prostaglandins, drugs for erectile dysfunction, drugs acting on central nervous system, anti-diarrhoeal antidiuretic agents, and generally any other drug for which taste masking is desired.


Specific examples of drugs of the above therapeutic categories include but are not limited to nizatidine, cimetidine, ranitidine, famotidine, roxatidine, etinidine, lupitidine, nifentidine, niperitone, sulfotidine, tuvatidine, zaltidine, erythromycin, penicillin, ampicillin, roxithromycin, clarithromycin, psyllium, ciprofloxacin, theophylline, nifedipine, prednisone, prednisolone, ketoprofen, acetaminophen, ibuprofen, dexibuprofen lysinate, flurbiprofen, naproxen, codeine, morphine, sodium diclofenac, acetylsalicylic

acid, caffeine, pseudoephedrine, phenylpropanolamine, diphenhydramine, chlorpheniramine, dextromethorphan, berberine, mefenamic acid, flufenamic acid, astemizole, terfenadine, phenytoin, guaifenesin, N-acetylprocainamide hydrochloride, and pharmaceutically acceptable salts or derivatives thereof.

5 In particular, low dose drugs such as enalapril, lorazepam, zolmitriptan, domperidon, selegiline, ondansetron, mirtazepine, hyosyamine sulphate, risperidone, citalopram, olanzapine, rizatriptan, piroxicam, desloratadine, cetirizine, loperamide, sildenafil, and topiramate and pharmaceutically acceptable salts or derivatives thereof may be used.

10 Examples of cationic polymers with dimethylaminoethyl groups include various grades of polymers commercially available from Rohm Pharma, Germany. In particular, Eudragit® E-100 and Eudragit® EPO may be used. In presence of an acid, Eudragit® E-100 and Eudragit® EPO form water soluble salts thus providing gastrosoluble film coatings. Eudragit® E films swell and are permeable in water and buffer solutions above  
15 pH 5 and is soluble in gastric fluid below pH 5. The average molecular weight of Eudragit® E is about 150,000 and it neither contains any plasticizers nor requires their addition for processing. The Eudragit® E-100 is present in an amount sufficient to mask the otherwise disagreeable taste of the medicament while in the mouth of the user. The drug to Eudragit® ratio generally is less than or equal to one to two and, in particular is  
20 about 1:1.75.

Eudragit®E polymers are methacrylic acid derivatives with a dimethylaminoethyl group. According to the fourth addition of the Handbook of Pharmaceutical Excipients, Eudragit E is a cationic polymer based on dimethylaminoethyl methacrylate and other  
25 neutral methacrylic acid esters. It is soluble in gastric fluid as well as in weakly acidic buffer solutions (up to pH of approximately 5). The structure of Eudragit E is given in the handbook as:



where:  $R^1 = R^3 = CH_3$

$R^2 = CH_2CH_2N(CH_3)_2$

$R^4 = CH_3, C_4H_9$

- 5            In one of the embodiments, the taste masked dosage form may further include other additives such as cellulose esters, talc, magnesium stearate and pigments which decrease the tendency of the Eudragit® polymer to agglomerate and thereby produce a more uniform surface on the nonpareil seed. Appropriate examples of cellulose esters include cellulose acetate, cellulose acetate butyrate, cellulose triacetate, ethyl cellulose and
- 10        mixtures thereof.

- Examples of suitable inert cores include water soluble and water insoluble particles, ideally having a size greater than about 100 microns. Specific examples of suitable seeds or cores that may be used in the dosage forms include inert cores prepared from directly compressible dibasic calcium phosphate; directly compressible sugar such as
- 15        directly compressible mannitol commercially available as PEARLITOL® SD 200 by Roquette Freres S.A., France; microcrystalline cellulose such as those commercially available as Ethispheres®, made of 100 % microcrystalline cellulose and which offers a good alternative for sugar-sensitive users and are available in particle sizes of 200 to 1000 micron; and nonpareil sugar seeds marketed by different manufacturers under different
- 20        trade names. These are available in different sizes ranging from 20 to 2000 microns.

Besides the above materials, the taste masked dosage form may include one or more pharmaceutically inert excipients such as diluents, binders, disintegrants, coloring

agents, flavoring agents, stabilizers, surfactants, lubricants/glidants, plasticizers and preservatives which are well known in the art of pharmaceutical formulations.

In another embodiment, taste masked dosage forms of unpleasant tasting drugs may be prepared by preparing a solution and/or dispersion of one or more unpleasant  
5   tasting drug and a low amount of one or more cationic polymers, optionally with other additives and loading the inert core with the above solution/dispersion of drug; and forming into a suitable dosage form. Again, the one or more cationic polymers may have a dimethylaminoethyl ammonium group

The solution/dispersion of the drug may be loaded over the inert core using any  
10   conventional technique known in the prior art such as granulation, spray coating, or coacervation techniques. In particular, the spray coating technique may be used.

Loading of the solution/dispersion of the drug over the inert core by a spray coating technique may be carried out by a process that includes the steps of dissolving the unpleasant tasting drug and cationic polymer in the solvent and spraying the solution over  
15   inert cores in a fluidized bed coater, such as Glatt Fluid Bed Wurster HS Coater. Air is passed through a bed of the inert core particles to fluidize them, and the solvent solution of the drug- polymer is sprayed onto the fluidized bed. The air passing through the bed dries the loaded core particles. The drug loaded cores may then be used in combination with various excipients, flavors, and colors to make a chewable, water dispersible or mouth  
20   dissolving tablet. These drug loaded cores may also be placed in a capsule to provide sprinkle capsules or may be suspended in suitable solvent to make suspensions.

Loading by a granulation process may be carried out by conventional techniques using a rapid mixer granulator or a fluid bed granulator. For loading by a coacervation process, homogenizer may be used.

25       Examples of suitable organic solvents used for the preparation of the solution/dispersion of drug include acetone, methanol, ethyl alcohol, isopropyl alcohol, water and mixtures thereof. Other examples include n-butyl alcohol, propylene glycol, ethylene glycol, monobutyl ether, methyl ethyl ketone, cyclohexanone, methylene chloride, chloroform, carbon tetrachloride, trichloroethylene, tetrachloroethylene, ethyl  
30   acetate, n-butyl acetate, propylene glycol acetate, toluene and mixtures thereof.

The following examples further exemplify the inventions and are not intended to limit the scope of the inventions

### EXAMPLE 1

Ingredient	Quantity (mg)
Topiramate	15
Eudragit® EPO	26
Ethyl cellulose (low viscosity)	3.7
Titanium dioxide	1.0
Nonpareil seeds	45.3
Talc	8.9
Isopropyl alcohol/Water (3:1)	q.s.
Total	100

Process:

- 5 Weighed quantities of topiramate, Eudragit® EPO and ethyl cellulose were dissolved in a suitable quantity of an isopropyl alcohol/water mixture to prepare the drug-polymer solution. Talc and titanium dioxide were then added to the above solution. Nonpareil seeds were placed in a Glatt Fluid Bed Wurster HS Coater and a drug polymer solution was sprayed on them. The resulting coated beads were cured by keeping them at room
- 10 temperature for 24 hours. These coated beads were filled into a hard gelatin capsule. The formulation of Example 1 had a ratio of drug (topiramate) to cationic polymer (Eudragit® EPO) of 15 to 26 (i.e., 1 to 1.733).

### EXAMPLE 2

Ingredient	Quantity (mg)
Desloratadine	5.05
Eudragit® EPO	7.50
Ethyl cellulose	5.0
Talc	5.0
Isopropyl alcohol	q.s.
Water	q.s.
Nonpareil seeds	20.0
Total	42.55

Process:

- 15 Weighed quantities of desloratadine, Eudragit® EPO and ethyl cellulose were dissolved in a suitable quantity of an isopropyl alcohol/water mixture to prepare the drug-polymer solution. Talc was then added to the above solution. Nonpareil seeds were placed in a Glatt Fluid Bed Wurster HS Coater and the drug-polymer solution was sprayed on them.

The resulting coated beads were cured by keeping them at room temperature for 24 hours. These coated beads were filled into a hard gelatin capsule. The formulation of Example 2 had a ratio of drug (desloratadine) to cationic polymer (Eudragit® EPO) of 5.05 to 7.50 (i.e., 1 to 1.49).

5

**EXAMPLE 3**

Ingredient	Quantity (gm)
Desloratadine	20.2
Eudragit® E PO	30.0
Ethyl cellulose	20.0
Talc	20.0
Isopropyl alcohol	q.s.
Water	q.s.
Nonpareil seeds	80.0
Total	170.20

Process:

The process for producing the formulation of Example 3 was the same as the process used for Example 2. The formulation of Example 3 had a ratio of drug (desloratadine) to cationic polymer (Eudragit® EPO) of 20.2 to 30.0 (i.e., 1 to 1.49).

10


While several particular forms of the inventions have been described, it will be apparent that various modifications and combinations of the inventions detailed in the text can be made without departing from the spirit and scope of the inventions. Finally, it is contemplated that any single feature or any combination of optional features of the inventive variations described herein may be specifically excluded from the claimed inventions and be so described as a negative limitation. Accordingly, it is not intended that the inventions be limited, except as by the appended claims.

15

## WE CLAIM:

- 1        1. A taste-masked pharmaceutical dosage form comprising one or more drugs and  
2        one or more cationic polymers synthesized from dimethylaminoethyl methacrylate  
3        and neutral methacrylic acid esters, wherein the wt/wt ratio of the drug to polymer  
4        is less than about one to two.
- 1        2. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2        wt/wt ratio of the drug to polymer is less than approximately 1:1.7.
- 1        3. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2        wt/wt ratio of the drug to polymer is less than approximately 1:1.5.
- 1        4. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2        drug comprises one or more of H<sub>2</sub> receptor antagonists, antibiotics, analgesics,  
3        cardiovascular agents, peptides or proteins, hormones, anti-migraine agents, anti-  
4        coagulant agents, anti-emetic agents, anti-hypertensive agents, narcotic  
5        antagonists, chelating agents, anti-anginal agents, chemotherapeutic agents,  
6        sedatives, anti-neoplastics, prostaglandins, drugs for erectile dysfunction, drugs  
7        acting on central nervous system, anti-diarrhoeal and anti-diuretic agents.
- 1        5. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2        drug comprises one or more of nizatidine, cimetidine, ranitidine, famotidine,  
3        roxatidine, etinidine, lupitidine, nifentidine, niperitone, sulfotidine, tuvatidine,  
4        zaltidine, erythromycin, penicillin, ampicillin, roxithromycin, clarithromycin,  
5        psyllium, ciprofloxacin, theophylline, nifedipine, prednisone, prednisolone,  
6        ketoprofen, acetaminophen, ibuprofen, dexibuprofen lysinate, flurbiprofen,  
7        naproxen, codeine, morphine, sodium diclofenac, acetylsalicylic acid, caffeine,  
8        pseudoephedrine, phenylpropanolamine, diphenhydramine, chlorpheniramine,  
9        dextromethorphan, berberine, mefenamic acid, flufenamic acid, astemizole,  
10        terfenadine, phenytoin, guaifenesin, N-acetylprocainamide HCl and  
11        pharmaceutically acceptable salts or derivatives thereof.
- 1        6. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2        drug comprises one more unpleasant tasting drugs.

- 1 7. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2 drug comprises a low dose drug.
- 1 8. The taste masked pharmaceutical dosage form according to claim 7 wherein the  
2 low dose drug comprises one or more of enalapril, lorazepam, zolmitriptan,  
3 domperidon, selegiline, ondansetron, mirtazepine, hyosyamine sulphate,  
4 risperidone, citalopram, olanzapine, rizatriptan, piroxicam, desloratadine,  
5 cetirizine, loperamide, sildenafil, topiramate, and pharmaceutically acceptable salts  
6 or derivatives thereof.
- 1 9. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2 cationic polymer includes a dimethylaminoethyl group.
- 1 10. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2 cationic polymer has the following formula:



3 where:  $R^1 = R^3 = \text{CH}_3$

4  $R^2 = \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$

5  $R^4 = \text{CH}_3, \text{C}_4\text{H}_9.$

- 1 11. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2 cationic polymer comprises a polymers commercially available as Eudragit®.
- 1 12. The taste masked pharmaceutical dosage form according to claim 11 wherein the  
2 Eudragit® comprises one or both of Eudragit® E-100 and Eudragit® EPO.




- 1 13. The taste masked pharmaceutical dosage form according to claim 12 wherein the  
2 Eudragit® comprises Eudragit® E-100.
- 1 14. The taste masked pharmaceutical dosage form according to claim 12 wherein the  
2 Eudragit® comprises Eudragit® EPO.
- 1 15. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2 dosage form further comprises other additives.
- 1 16. The taste masked pharmaceutical dosage form according to claim 15 wherein the  
2 additives comprise one or more of cellulose ester, talc, magnesium stearate and  
3 pigments.
- 1 17. The taste masked pharmaceutical dosage form according to claim 16 wherein the  
2 cellulose ester comprises one or more of cellulose acetate, cellulose acetate  
3 butyrate, cellulose triacetate, ethyl cellulose and mixtures thereof.
- 1 18. The taste masked pharmaceutical dosage form according to claim 1 wherein a drug  
2 solution/dispersion is coated onto a water soluble or insoluble inert core.
- 1 19. The taste masked pharmaceutical dosage form according to claim 18 wherein the  
2 water soluble or insoluble inert core comprises one or more of directly  
3 compressible dibasic calcium phosphate, directly compressible sugar,  
4 microcrystalline cellulose, and nonpareil sugar seeds.
- 1 20. The taste masked pharmaceutical dosage form according to claim 19 wherein the  
2 inert core comprises directly compressible mannitol.
- 1 21. The taste masked pharmaceutical dosage form according to claim 18 wherein the  
2 inert core has a particle size greater than about 100 microns.
- 1 22. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2 dosage form is selected from the group consisting of sprinkles, chewable tablets,  
3 mouth dissolving tablets, water dispersible tablets, effervescent tablets and  
4 suspensions.

- 1 23. The taste masked pharmaceutical dosage form according to claim 1 wherein the  
2 dosage form further comprises one or more pharmaceutically inert excipients.
- 1 24. The taste masked pharmaceutical dosage form according to claim 23 wherein the  
2 one or more pharmaceutically inert excipient comprise one or more of diluents,  
3 binders, disintegrants, coloring agents, flavoring agents, stabilizers, surfactants,  
4 lubricants, glidants, plasticizers and preservatives.
- 1 25. A process for the preparation of a taste masked dosage form of one or more  
2 unpleasant tasting drugs, the process comprising:  
3 dissolving or dispersing one or more drugs and one or more cationic  
4 polymers in a solvent; and  
5 loading a solution and/or dispersion of one or more drugs and one or more  
6 cationic polymer onto an inert core  
7 wherein the one or more cationic polymers are synthesized from  
8 dimethylaminoethyl methacrylate and neutral methacrylic acid esters and the wt/wt  
9 ratio of the drug to polymer in the dosage form is less than about one to two.
- 1 26. The process according to claim 25 wherein the loading of the drug  
2 solution/dispersion over the inert core is carried out by one or more of granulation,  
3 spray coating or coacervation technique.
- 1 27. The process according to claim 25 wherein the loading of the drug  
2 solution/dispersion over the inert core is carried out by spray coating.
- 1 28. The process according to claim 25 wherein the loading of the drug  
2 solution/dispersion over the inert core is carried out by granulation.
- 1 29. The process according to claim 25 wherein the loading of the drug  
2 solution/dispersion over the inert core is carried out by coacervation.
- 1 30. The process according to claim 25 wherein the solvent comprises one or more of  
2 acetone, methanol, ethyl alcohol, isopropyl alcohol, water, n-butyl alcohol,  
3 propylene glycol, ethylene glycol, monobutyl ether, methyl ethyl ketone,  
4 cyclohexanone, methylene chloride, chloroform, carbon tetrachloride,

5 trichloroethylene, tetrachloroethylene, ethyl acetate, n-butyl acetate, propylene  
6 glycol acetate, toluene and mixtures thereof.

1 31. The process according to claim 25 wherein the cationic polymer includes a  
2 dimethylaminoethyl group.

1 32. The process according to claim 25 wherein the cationic polymer has the following  
2 formula:



3 where:  $R^1 = R^3 = \text{CH}_3$   
4  $R^2 = \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$   
5  $R^4 = \text{CH}_3, \text{C}_4\text{H}_9$ .

1 33. The process according to claim 25 wherein the cationic polymer comprises a  
2 polymer commercially available as Eudragit®.


1 34. The process according to claim 25 wherein the Eudragit® comprises one or both of  
2 Eudragit® E-100 and Eudragit® EPO.

1 35. A taste masked pharmaceutical dosage form comprising:  
2 an inert core;  
3 one or more drugs; and  
4 one or more cationic polymers,  
5 wherein one or more cationic polymers are synthesized from dimethylaminoethyl  
6 methacrylate and neutral methacrylic acid esters, the one or more drugs and the

one or more cationic polymers form a layer around the inert core, and the wt/wt ratio of the drug to polymer in the dosage form is less than about one to two.

36. The taste masked pharmaceutical dosage form according to claim 35 wherein the cationic polymer includes a dimethylaminoethyl group.

37. The taste masked pharmaceutical dosage form according to claim 35 wherein the cationic polymer has the following formula:



where:  $R^1 = R^3 = \text{CH}_3$

$R^2 = \text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$

$R^4 = \text{CH}_3, \text{C}_4\text{H}_9$ .

38. The taste masked pharmaceutical dosage form according to claim 35 wherein the cationic polymer comprises a polymer commercially available as Eudragit®.

39. The taste masked pharmaceutical dosage form according to claim 35 wherein the Eudragit® comprises one or both of Eudragit® E-100 and Eudragit® EPO.

40. The taste masked pharmaceutical dosage form according to claim 35 wherein the inert core comprises one or more of directly compressible dibasic calcium phosphate, directly compressible sugar, microcrystalline cellulose, and nonpareil sugar seeds.

# INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/IB 03/03779

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K9/16 A61K47/32

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199528 Derwent Publications Ltd., London, GB; Class A96, AN 1995-212873 XP002265001 & JP 07 126153 A (OHTA SEIYAKU KK), 16 May 1995 (1995-05-16) abstract	1,4-6, 9-11, 15-19, 21, 25-27, 30-33, 35-38,40
A	US 4 758 437 A (T.SONOBET AL.) 19 July 1988 (1988-07-19) claims examples	1-40
A	US 4 708 867 A (C.H.HSIAO ET AL.) 24 November 1987 (1987-11-24) claims column 1, line 62 - line 68	1-40
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

16 December 2003

Date of mailing of the international search report

13/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

## INTERNATIONAL SEARCH REPORT

Internal Application No.

PCT/1b 03/03779

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 17742 A (ELAN) 15 April 1999 (1999-04-15) cited in the application claims examples ---	1-40
A	EP 0 266 113 A (AMERICAN HOME PRODUCTS) 4 May 1988 (1988-05-04) cited in the application claims ---	1-40
A	US 4 663 150 A (D.E.PANUZ ET AL.) 5 May 1987 (1987-05-05) claims examples -----	1-40

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/IB 03/03779

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 7126153	A	16-05-1995	NONE	
US 4758437	A	19-07-1988	JP 1007047 B	07-02-1989
			JP 1523698 C	12-10-1989
			JP 58116414 A	11-07-1983
			AT 386743 B	10-10-1988
			AT 460682 A	15-03-1988
			CA 1200494 A1	11-02-1986
			ES 8402156 A1	16-04-1984
			GR 77096 A1	06-09-1984
			IT 1200966 B	27-01-1989
			KR 8601147 B1	18-08-1986
			MX 7567 E	27-10-1989
			PT 76023 A , B	01-01-1983
US 4708867	A	24-11-1987	NONE	
WO 9917742	A	15-04-1999	AU 9182498 A	27-04-1999
			CA 2304630 A1	15-04-1999
			EP 1027036 A2	16-08-2000
			WO 9917742 A2	15-04-1999
			JP 2001518490 T	16-10-2001
			US 6153220 A	28-11-2000
			ZA 9809013 A	13-04-1999
EP 266113	A	04-05-1988	US 4760093 A	26-07-1988
			AT 63464 T	15-06-1991
			AU 594203 B2	01-03-1990
			AU 7950987 A	28-04-1988
			CA 1290251 C	08-10-1991
			DE 3770116 D1	20-06-1991
			EP 0266113 A1	04-05-1988
			ES 2032450 T3	16-02-1993
			GR 3002108 T3	30-12-1992
			IE 61952 B1	30-11-1994
			JP 2542400 B2	09-10-1996
			JP 63112513 A	17-05-1988
			KR 9513751 B1	15-11-1995
US 4663150	A	05-05-1987	IE 55745 B1	02-01-1991
			AT 53176 T	15-06-1990
			BE 899293 A1	16-07-1984
			CH 660688 B	15-06-1987
			DE 3482374 D1	05-07-1990
			EP 0122077 A2	17-10-1984
			JP 1771837 C	14-07-1993
			JP 4066207 B	22-10-1992
			JP 59219219 A	10-12-1984
			PH 18904 A	30-10-1985
			US 4820521 A	11-04-1989